In the findings from a multi‐country survey, PAEs including low sexual interest, anxiety, and insomnia occurred in 50%, 34%, and 14% of patients on CDK4/6i treatment, respectively, severely affecting their quality of life.15 This evidence concerns the gene CDK4 and insomnia measurement.